Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis
New immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good t...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2015-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/455 |